Literature DB >> 25843733

Epstein-Barr virus-associated lymphomas.

Ewelina Grywalska1, Jacek Rolinski2.   

Abstract

The Epstein-Barr virus (EBV) is the first identified human virus with a proven association with the pathogenesis of cancer. To maintain the integrity of the viral genome and to "get out" of the control of the host immune system, in the phase of the latent infection EBV shows the expression of several genes, including genes for six nuclear antigens, three latent membrane proteins, two short non-coding RNAs, and BamHI-A rightward transcripts. The different patterns of expression of these latent genes determine the occurrence of different types of latency in the pathogenesis of particular malignancies. One of the most important features of EBV is its ability to infect various cell types and the consequent variety of diseases. It has been shown that in humans, EBV infection may lead to the development of cancers, including those derived from hematopoietic cells. Although cases of T-cell and epithelial cell infections have been documented, EBV is characterized mainly by tropism for B lymphocytes, and under certain conditions their infection may result in transformation to B-cell lymphoma. This article discusses the mechanisms leading to the development of EBV-dependent lymphomas, and briefly characterizes these diseases.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25843733     DOI: 10.1053/j.seminoncol.2014.12.030

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  38 in total

1.  Connecting Cancer to Its Causes Requires Incorporation of Effects on Tissue Microenvironments.

Authors:  James DeGregori
Journal:  Cancer Res       Date:  2017-07-28       Impact factor: 12.701

Review 2.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 3.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Characterization of the rapamycin-inducible EBV LMP1 activation system.

Authors:  Sang Yong Kim; Jung-Eun Kim; Jiyeon Won; Yoon-Jae Song
Journal:  J Microbiol       Date:  2015-10-02       Impact factor: 3.422

5.  Lactic Acid Downregulates Viral MicroRNA To Promote Epstein-Barr Virus-Immortalized B Lymphoblastic Cell Adhesion and Growth.

Authors:  Xiaohui Mo; Fang Wei; Yin Tong; Ling Ding; Qing Zhu; Shujuan Du; Fei Tan; Caixia Zhu; Yuyan Wang; Qian Yu; Yeqiang Liu; Erle S Robertson; Zhenghong Yuan; Qiliang Cai
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

6.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

7.  Can Epstein-Barr virus play a role in upper urinary tract urothelial carcinomas?

Authors:  Y Dere; S Ekmekçi; İ Akarken; Ü Küçük
Journal:  Ann R Coll Surg Engl       Date:  2020-06-15       Impact factor: 1.891

8.  Laryngeal Epstein-Barr Virus-Associated Smooth Muscle Tumor in an Undernourished Child.

Authors:  Ciro Dantas Soares; Roman Carlos; Juan Pablo Díaz Molina; Thayná Melo de Lima Morais; Oslei Paes de Almeida
Journal:  Head Neck Pathol       Date:  2018-08-17

9.  Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma.

Authors:  Dong Won Baek; Jung Min Lee; Juhyung Kim; Hee Jeong Cho; Sang Kyun Sohn; Ji Yeon Ham; Soon Hee Chang; Joon Ho Moon; Deok-Hwan Yang
Journal:  Blood Res       Date:  2021-06-30

10.  Simiao Qingwen Baidu decoction inhibits Epstein-Barr virus-induced B lymphoproliferative disease and lytic viral replication.

Authors:  Xianhui Yang; Lingling Liu; Huijuan Zhang; Xiaoxu Sun; Yongbin Yan; Ruiying Ran
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.